Cognite Launches Multi-Site Manufacturing Data Connectivity Initiative with NOVA Chemicals to Reshape Global Operations Across 11 Assets
24.9.2024 15:00:00 CEST | Business Wire | Press release
Cognite, a globally recognized leader in industrial software, and NOVA Chemicals Corporation (“NOVA Chemicals”), a leading North American producer of polyethylene, announced the launch of a multi-site manufacturing data connectivity initiative to accelerate and scale digital transformation solutions across NOVA Chemicals’ organization.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240923486643/en/
NOVA Chemicals will leverage Cognite's Industrial DataOps platform, Cognite Data Fusion®, to consolidate data from multiple source systems, such as SAP, Hexagon, and Aspen IP21, into a real-time industrial knowledge graph. This open, flexible, and scalable digital representation of NOVA Chemicals' operations would enable seamless data flow from source systems to enterprise technology solutions, improving access and trust in their data and reducing time spent on data discovery.
"At NOVA, we manage asset information in multiple independent systems, which can make the process of getting all of the right information to the right people highly complex and time-consuming,” said David Lyford, Operational Excellence Leader at NOVA Chemicals. “The Cognite data platform would enable us to view and utilize our siloed industrial data in a contextualized manner. This improves timely access to critical information, strengthens our core operations, and deepens our understanding of our processes. As a key element of our digital transformation strategy, an enterprise contextualization platform empowers us to enhance decision-making and secure a competitive business advantage."
NOVA Chemicals aims to be a leading North American polyethylene producer by delivering innovative solutions that help make everyday life healthier and safer. NOVA Chemicals will support this by scaling its manufacturing data connectivity initiatives across 11 manufacturing assets, addressing critical business challenges that will create net recurring value within the manufacturing organization, such as:
- Improved access to data in the field and for operations experts, reducing time spent on data discovery
- Efficiency gains across isolation planning, maintenance planning for routine and turnaround, troubleshooting, and operations support
- Increased equipment insights to prevent failures and reduce costs while improving safety, process consistency, and empowering frontline workers
- Improved scalability of enterprise technology solutions that help maintain competitiveness via lower operating costs through improved efficiency and accelerating sustainability initiatives
Join NOVA at IMPACT 2024, the world’s largest industrial user conference, October 14-15 in Houston, Texas, to learn more about the unmatched data management and comprehensive AI capabilities of Cognite Data Fusion. Register here:.cognite.com/en/impact-conference
About Cognite
Cognite makes Generative AI work for industry. Leading energy, manufacturing, and power & renewables enterprises choose Cognite to deliver secure, trustworthy, and real-time data to transform their asset-heavy operations to be safer, more sustainable, and more profitable. Cognite provides a user-friendly, secure, and scalable platform that makes it easy for all decision-makers, from the field to remote operations centers, to access and understand complex industrial data, collaborate in real-time, and build a better tomorrow. Visit us at www.cognite.ai and follow us on LinkedIn and X.
About NOVA Chemicals Corporation
At NOVA Chemicals, our driving purpose is to reshape plastics for a better world by delivering innovative solutions that make everyday life healthier, safer, and more efficient. With a focus on outstanding research and development, our diverse portfolio enables our customers and their brands to create monomaterial products and packaging that are suitable for circular applications, including food packaging, heavy duty sacks, hygiene films, shrink and stretch wrap, e-commerce protective packaging, household bags and wrap, and trash bags and liners. Our employees work every day to ensure decisions and actions are made under our commitment to Responsible Care®, developing innovative solutions that enable the circular economy while being a responsible steward of the environment.
NOVA Chemicals, headquartered in Calgary, Alberta, Canada, has 2,600 employees worldwide and is wholly owned by Mubadala Investment Company of the Emirate of Abu Dhabi, United Arab Emirates.
Learn more at www.novachem.com or follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240923486643/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom